The Medicines and Healthcare products Regulatory Agency (MHRA) has granted Myqorzo (aficamten) a marketing authorisation across the UK for the treatment of symptomatic (New York Heart Association, NYHA class II-III) obstructive hypertrophic cardiomyopathy (oHCM). At the same time, the National Institute for Health and Care Excellence (NICE)… Read More
The National Institute for Health and Care Excellence (NICE) has recommended cemiplimab for the treatment of advanced cervical cancer. The immunotherapy, developed by biotechnology company Regeneron, has been recommended in England and Wales to treat recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy… Read More
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Darzalex (daratumumab) as a combination therapy for untreated multiple myeloma. NICE recommended the therapy, developed by Johnson & Johnson, with bortezomib, lenalidomide and dexamethasone (D-VRd) for untreated multiple myeloma in adults when an autologous stem cell transplant (ASCT)… Read More
The National Institute for Health and Care Excellence (NICE) has recommended Nucala (mepolizumab) as an add-on treatment for NHS patients with COPD. The draft final guidance recommends mepolizumab as an add-on maintenance treatment option for adult patients with uncontrolled COPD with raised blood eosinophils, if they are having… Read More
The National Institute for Health and Care Excellence (NICE) has recommended cemiplimab in combination with platinum-based chemotherapy to treat patients with non-small cell lung cancer (NSCLC). Cemiplimab is a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells, which was shown to block cancer cells from… Read More
The National Institute for Health and Care Excellence (NICE) has recommended Rystiggo (rozanolixizumab) as a treatment for adults with antibody-positive generalised myasthenia gravis (gMG). Rystiggo is the first targeted therapy for gMG, a rare, chronic autoimmune neuromuscular disease. The condition is characterised by fluctuating muscle weakness and fatigue and can lead to difficulties with vision,… Read More
Eli Lilly’s appeal against guidance which did not recommend donanemab has been upheld, forcing authorities to reconsider the drug for NHS use. The National Institute for Health and Care Excellence (NICE) published the outcome for Lilly’s appeal, after final draft guidance had not recommended NHS reimbursement of donanemab for the treatment of mild cognitive… Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, more effective treatments were found for both HIV and chronic wounds. Elsewhere, €40,000… Read More
News round-up for 23 – 27 February by Bruno Quinney, Content Team at DDW. This week in drug discovery, more effective treatments have been found for both HIV and chronic wounds. Elsewhere, €40,000 is up for grabs in prostate cancer research. The top stories: … Read More
The National Institute for Health and Care Excellence (NICE) has recommended the first bispecific antibody for the treatment of follicular lymphoma (FL). Tepkinly (epcoritamab), developed by biopharmaceutical company AbbVie, has been recommended to the NHS as an option to treat adult patients with FL whose cancer has returned… Read More
A new UK initiative aims to shake-up approaches to clinical trial design and delivery by developing new ways to speed up the process and drive improvements. The Medical Research Council Centre of Research Excellence in Clinical Trial Innovation in partnership with the National Institute for Health and… Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a trade agreement between the UK and the US promised to support… Read More
News round-up for 1 – 5 December by Bruno Quinney, Content Team at DDW. This week in DDW, a trade agreement between the UK and the US promises to support the life sciences industry and secure access to drugs. Elsewhere, novel therapies could break new ground in treating neurodegenerative diseases. The… Read More
A trade deal has been agreed between the UK and the US, which the governments says will secure and expand access to drugs, safeguard the medicines supply chain, and “drive crucial investment while supporting UK patients and industries”. The deal – part of the UK-US… Read More
The National Institute for Health and Care Excellence (NICE) has recommended Talvey (talquetamab) for use in the NHS for treating relapsed or refractory myeloma (RRMM) in adults. Talquetamab, developed by Johnson & Johnson, is a first-in-class bispecific antibody targeting the GPRC5D receptor on myeloma cells. The treatment… Read More
News round-up for 8-12 September by DDW Editor Reece Armstrong. Fast-track designations by the FDA, clinical trials to advance mental health and pharma team-ups to bring innovations to market are just some of the stories in this week’s news round-up. The top stories FDA fast-tracks Sanofi’s AMD gene therapy… Read More
